In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-21 of 21 for your search:

Drug:  ondansetron
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer

Phase: Phase III, Phase II
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069401, U10CA037420, URCC-U1902, URCC-0114, NCI-5857, NCI-P02-0223, NCT00040742

Phase III Randomized Study of Ondansetron in Patients With Advanced Cancer and Chronic Nausea and Emesis Not Due to Antineoplastic Therapy

Phase: Phase III
Type: Supportive care
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: NCCTG-989201, NCI-P00-0168, NCT00006348

Phase III Randomized Study of 3 Regimens For the Prevention of Delayed Nausea After Chemotherapy in Patients With Chemotherapy-Naive Cancer

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: URCC-U3901, NCI-P01-0180, NCT00020657

Phase III Study of Ondansetron vs Droperidol for the Treatment of Immunotherapy-Induced Emesis (Summary Last Modified 03/92)

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-92-C-0043, NCI-T91-0277N, T91-0277

Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 16 and over
Sponsor: Other
Protocol IDs: SC19, CAN-NCIC-SC19, CDR0000068627, NCT00016380

Phase III Randomized Study of Acupressure to Control Chemotherapy-Induced Nausea in Children With Central Nervous System or Solid Tumors Receiving Cisplatin-Containing Chemotherapy

Phase: Phase III
Type: Supportive care
Status: Closed
Age: 4 to 18
Sponsor: NCI
Protocol IDs: SCUSF-1202, COG-ACCL1032, ACCL1032, NCT01346267

Phase II Randomized Study of Acupressure and Acustimulation Wrist Bands for the Prevention of Chemotherapy Induced Nausea and Vomiting

Phase: Phase II
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: URCC-U3997, NCI-V99-1528, NCT00003817

Phase II Study of CDDP/CBDCA with Ondansetron or Granisetron and G-CSF in Patients with Stage III/IV Epithelial Ovarian Cancer

Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: no age specified
Sponsor: Other
Protocol IDs: NBSG-9204, NCI-V92-0153

Phase II Study of CDDP/CTX/DOX with G-CSF and Ondansetron in Patients with Metastatic or Recurrent Adenocarcinoma of the Endometrium

Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NBSG-9206, NCI-V92-0158

10.

Phase II Study of Single-Dose Intravenous Ondansetron/Dexamethasone to Control Acute Vomiting Followed by Oral Dexamethasone/Prochlorperazine to Control Delayed Vomiting in Patients Receiving High-Dose Doxorubicin (Summary Last Modified 12/93)

Phase: Phase II
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-93098, NCI-V93-0318

11.

Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy

Phase: Phase II
Type: Supportive care
Status: Temporarily closed
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: Rafa protocol THC002/NVP, NCT00285051

12.

Randomized Study of the Efficacy of Patient Information in Alleviating Nausea and Emesis in Cancer Patients Receiving Chemotherapy (Summary Last Modified 01/2001)

Phase: No phase specified
Type: Educational/Counseling/Training
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: URCC-3996, NCI-P00-0160, NCT00005994

13.

Double-Blind Comparison of Intravenous GR-C507/75 vs Metoclopramide in the Prevention of Nausea and Vomiting Associated with a Multiple-Day Regimen of Cisplatin in Patients with Testicular Cancer (Summary Last Modified 03/89)

Phase: No phase specified
Type: Supportive care
Status: Closed
Age: 15 and over
Sponsor:
Protocol IDs: MSKCC-88121, NCI-V89-0005

14.

Open-Label Evaluation of a Single Intravenous Dose of GR 38032F for the Prevention of Nausea and Vomiting Associated with High-Dose Cisplatin (Summary Last Modified 06/89)

Phase: No phase specified
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-88145, NCI-V89-0049

15.

Double-Blind Evaluation of Intravenous vs Intravenous plus Oral Ondansetron in the Prevention of Nausea and Vomiting in Cancer Patients Receiving a Multiple-Day Regimen of CDDP (Summary Last Modified 11/91)

Phase: No phase specified
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: TCSC-S3A-402, NCI-V91-0142

16.

Pilot Open-Label Study of Intravenous Ondansetron/Dexamethasone in Patients with Nausea and Vomiting Associated with Multiple-Day Cisplatin Chemotherapy (Summary Last Modified 11/92)

Phase: No phase specified
Type: Supportive care
Status: Completed
Age: 18 to 90
Sponsor:
Protocol IDs: MSKCC-91068, NCI-V91-0166

17.

Evaluation of MDLO (Metoclopramide/Dexamethasone/Lorazepam/Ondansetron) for the Prevention of Acute Vomiting In Cancer Patients Receiving High-Dose Cisplatin (Summary Last Modified 11/92)

Phase: No phase specified
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-91072, NCI-V91-0180

18.

Randomized, Double-Blind, Comparative Study of Oral RG 12915 vs Intravenous Ondansetron for the Control of Acute and Delayed Vomiting Following High-Dose CDDP (Summary Last Modified 10/92)

Phase: No phase specified
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-92020A1, NCI-V92-0115

19.

Randomized, Double-Blind, Comparative Study of the Antiemetic Effectiveness of Single Dose IV Dolasetron Mesylate vs IV Ondansetron in Patients Receiving First-Line CDDP Chemotherapy (Summary Last Modified 06/93)

Phase: No phase specified
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-92141, NCI-V92-0193

20.

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Phase: No phase specified
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6140, NCI-2010-00801, UWCC-6140, UWCC-UW-6140, UWCC-05-9579-H/D, FHCRC-6140, MGI-FHCRC-6140, NCT00343863

21.

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Phase: No phase specified
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000445452, OHSU-HEM-03074-L, OHSU-1057, MERCK-OHSU-HEM-03074-L, NCT00248547

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map

Other Versions of this Site: Mobile | Español

Follow Us:

Twitter
YouTube
Facebook
RSS

NIH…Turning Discovery Into Health^®